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Abstract. A 73-year-old man with a history of lethargy, fever 
and dyspnea was admitted to Tottori University Hospital. A 
computed tomography (CT) scan revealed splenomegaly and 
diffusely spreading ground-glass opacities (GGOs) in both 
lungs. A video-assisted thoracoscopic surgery (VATS)-guided 
lung biopsy revealed intravascular proliferation of large atypical 
lymphoid cells in the arteries, veins and alveolar walls. The 
patient was diagnosed with intravascular large B-cell lymphoma 
(IVLBCL); he received 6 cycles of rituximab, cyclophospha-
mide, doxorubicin, vincristine and prednisolone (R-CHOP) 
immunochemotherapy and has remained in complete remission 
for >1 year. Although IVLBCL is a rare disease, it should be 
considered in the differential diagnosis of pulmonary diffuse 
lesions that present with GGOs on CT scans.
Introduction
Intravascular large B-cell lymphoma (IVLBCL) is a rare 
entity characterized by exclusive or predominant growth of 
neoplastic cells within the lumen of blood vessels. This disease 
was recently recognized as a subtype of diffuse large B-cell 
lymphoma by the World Health Organization (WHO) (1). 
The clinical presentation of IVLBCL varies widely due to 
occlusion of small vessels or capillaries in different organs. 
The most common clinical symptoms include fever, general 
fatigue, neurological manifestations and non-specific skin 
eruptions (2,3). Although autopsy findings have revealed that 
pulmonary involvement is also common in this disease, a 
primary presentation in the lung is uncommon and has rarely 
been described. In non-Hodgkin lymphoma (NHL), extra-
nodal disease accounts for 24-50% of all cases, whereas only 
34% of the cases include pulmonary lesions, with primary 
pulmonary lesions presenting in <1% of the patients (4). As 
early pulmonary IVLBCL diagnosis is difficult and treatment 
for pulmonary IVLBCL is less effective, the prognosis for the 
majority of the patients is poor (4). We herein report the case 
of a patient with pulmonary IVLBCL who was successfully 
treated with R-CHOP and has survived for >1 year.
Case report
A 73-year-old man visited a local clinic complaining of 
general malaise, dry cough, hoarseness, a 6-kg weight loss and 
fever. The patient was referred to our hospital, as no improve-
ment was observed after 3 months. The patient's medical 
history was unremarkable, he had never smoked and had no 
history of occupational dust exposure. On admission, there 
were no enlarged superficial lymph nodes, skin lesions, or 
neurological abnormalities There were no abnormal findings 
on chest auscultation. Laboratory tests revealed the following 
results: Total leukocyte count, 5,400 cells/mm3 (69% neutro-
phils, 11% lymphocytes, 20% monocytes, 0% basophils and 
eosinophils); hemoglobin concentration, 11.6 g/dl; mean 
corpuscular volume, 82.5 fl; reticulocyte percentage, 8%; 
platelet count, 117,000/µl; C-reactive protein, 17.9 mg/dl; 
ferritin, 5,720 ng/ml; serum lactate dehydrogenase, 562 U/l; 
and soluble interleukin-2 receptor, 8,313 U/ml. Hypoxemia 
was also present, with an arterial oxygen tension of 53.2 Torr 
(room air). The pulmonary function test results were within 
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normal limits, except for a reduction in the diffusion capacity 
of carbon monoxide (64.3% of the predicted value). There 
were no laboratory data suggestive of infection or autoim-
mune disease.
Chest radiography revealed diffusely spreading 
ground-glass opacities (GGOs) in both lungs, predominantly 
in the inferior lobes, but there were no signs of cardiac 
enlargement, pleural effusion, or enlarged mediastinal lymph 
nodes. Bilateral diffuse GGOs were also evident on computed 
tomography (CT) scans, but there were no signs of interlobular 
septal thickening or decreased volume. The spleen was also 
enlarged on CT (Fig. 1). Gallium scintigraphy also revealed 
diffuse and increased uptake in the lung field, as well as 
increased uptake in the spleen and splenomegaly.
Figure 1. Chest computed tomography showing (A-C) multiple ground glass opacities (arrows) in both lungs and (D) splenomegaly (arrowheads).
Figure 2. Histological diagnosis of intravascular large B-cell lymphoma. (A) Hematoxylin and eosin staining showing several large atypical cells (arrow). 
(B) CD20 immunostaining of atypical cells. (C) Negative CD5 immunostaining (D) CD34 immunostaining showing atypical cells mainly located within small 
vessels and alveolar wall capillaries (arrow). 
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At that point, the differential diagnosis included atypical 
pneumonia, eosinophilic pneumonia, hypersensitivity 
pneumonitis, pulmonary alveolar hemorrhage, pulmonary 
alveolar proteinosis and intravascular large B-cell lymphoma. 
However, a transbronchial lung biopsy (TBLB) could not be 
performed due to the patient's coughing. Antibiotic and steroid 
treatment was initiated, but the patient's general condition 
continued to deteriorate. A lung biopsy was then performed 
using video-assisted thoracoscopic surgery (VATS).
Histological examination of the bioptic specimen revealed 
several large atypical cells, mainly located within the small 
vessels and alveolar wall capillaries (Fig. 2A and D). These 
atypical cells also infiltrated an extravascular area of the 
stroma, with a patchy distribution in the enlarged interstitium 
throughout the lesion. Imunohistochemically, the atypical 
cells were positive for CD20 (Fig. 2B) but were negative for 
CD5 (Fig. 2C). Epstein-Barr virus (EBV)-encoded RNA 
in situ hybridization was also performed, but only a few posi-
tive cells were detected, ruling out involvement of EBV in this 
case. Bone marrow infiltration was not observed, although 
phagocytosis of neutrophils by macrophages was present at a 
very low frequency. The findings of the skin biopsy were unre-
markable. Based on these findings, the patient was diagnosed 
with IVLBCL.
As respiratory failure was progressing rapidly, steroid 
pulse therapy and oral cyclophosphamide (100 mg per day 
for 6  days) were administered until the histological results 
became available. After diagnosis was confirmed, six courses 
of R-CHOP immunochemotherapy were administered. The 
GGOs in the lung field rapidly disappeared and the respira-
tory status improved (Fig. 3). A positron emission tomography 
(PET)/CT scan after the completion of the sixth course revealed 
no uptake in the lung or spleen and the patient remains alive 
and symptom-free for >1 year.
The patient has provided his consent regarding the publica-
tion of the case details.
Discussion
IVLBCL is characterized by proliferation of atypical lymphoid 
cells within the lumen of capillaries. IVLBCL is a rare variant 
of diffuse large B-cell lymphoma that has been included in 
the WHO classification (5). The central nervous system (CNS) 
and skin are usually involved. By contrast, IVLBCL patients 
in Asian countries often exhibit hepatosplenomegaly, throm-
bocytopenia and fever, but CNS and skin involvement are 
rare (6,7). In the present case, the patient exhibited findings 
typical of an Asian patient. In addition, several pulmonary 
IVLBCL cases were recently reported in Asia (2-4).
Recently, fluorodeoxyglucose (FDG)‑PET/CT was shown 
to be useful for staging NHL (8), and several authors reported 
that FDG-PET/CT is a powerful tool for early diagnosis of 
IVLBCL (9); however, biopsy is essential. Due to its low inva-
siveness, TBLB is one of the most useful biopsy techniques 
for pulmonary lesions (4). In the present case, VATS-guided 
surgical biopsy was crucial, as TBLB could not be performed. 
If diffuse GGOs are present, IVLBCL should be included in 
the differential diagnosis, and a biopsy should be proactively 
performed.
The recommended treatment is systemic chemotherapy 
with an anthracycline-based regimen. However, the majority of 
IVLBCL cases are associated with poor prognosis. Recently, 
R-CHOP immunochemotherapy was shown to yield better 
results compared with CHOP (4,10,11). Our patient was treated 
with R-CHOP, and 1 year later there has been no recurrence. 
Pulmonary IVLBCL presenting with GGOs is exceedingly 
rare, but it should be considered in the differential diagnosis of 
respiratory disease presenting with GGOs.
Figure 3. Repeat chest computed tomography showing resolution of the multiple ground glass opacities (GGOs) in the lungs (arrows). (A and B) Multiple GGOs 
in both lungs were observed upon admission to the hospital. (C and D) The GGOs rapidly disappeared after treatment.
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